Stock IPSC CENTURY THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Century Therapeutics, Inc.

Equities

IPSC

US15673T1007

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 02:56:25 2024-04-25 pm EDT 		5-day change 1st Jan Change
3.085 USD +4.22% Intraday chart for Century Therapeutics, Inc. +4.87% -6.02%
Apr. 12 Piper Sandler Adjusts Price Target on Century Therapeutics to $9 From $10, Maintains Overweight Rating MT
Apr. 11 Syncona agrees to sell stake in investee company for GBP7.4 million AN

Business Summary

Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with unmet medical need. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-102, CNTY-107, CNTY-104, and CNTY-106. Its CNTY-101 is focused on targeting CD19 for relapsed, refractory B-cell lymphoma. CNTY-102 targets CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies. CNTY-107 is used of the treatment of solid tumors expressing Nectin-4. CNTY-106 is a multi-specific collaboration program for multiple myeloma.

Number of employees: 159

Sales per Business

USD in Million2022Weight2023Weight Delta
Allogeneic Cell Therapies
100.0 %
5 100.0 % 2 100.0 % -57.01%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
5 100.0 % 2 100.0 % -57.01%

Managers

Managers TitleAgeSince
Brent Pfeiffenberger CEO
 Chief Executive Officer - Dec. 03
Douglas Carr DFI
 Director of Finance/CFO - 18-09-30
Kenneth J. Dow CMP
 Compliance Officer - -
Gregory Russotti CTO
 Chief Tech/Sci/R&D Officer 57 19-12-31
Adrienne Farid COO
 Chief Operating Officer 62 21-03-31
Hyam Levitsky CTO
 Chief Tech/Sci/R&D Officer 66 19-04-30
Shane N. O. Williams HRO
 Human Resources Officer - -

Members of the board

Members of the board TitleAgeSince
Timothy Walbert BRD
 Director/Board Member 57 22-09-30
Joseph Jimenez CHM
 Chairman 64 19-07-31
Cynthia Butitta BRD
 Director/Board Member 70 21-01-31
Daphne Quimi BRD
 Director/Board Member 58 22-09-30
Alessandro Riva BRD
 Director/Board Member 63 21-04-30
Carlo Rizzuto BRD
 Director/Board Member 53 18-02-28
Kimberly Blackwell BRD
 Director/Board Member 55 21-04-30
Brent Pfeiffenberger CEO
 Chief Executive Officer - Dec. 03

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 64,817,863 57,084,390 ( 88.07 %) 0 88.07 %

Shareholders

NameEquities%Valuation
BAYER AG
19.56 %
12,675,838 19.56 % 53 M $
Versant Venture Management LLC
17.67 %
11,452,014 17.67 % 48 M $
FUJIFILM HOLDINGS CORPORATION
10.73 %
6,955,207 10.73 % 29 M $
Casdin Capital LLC
8.008 %
5,190,506 8.008 % 22 M $
Boxer Capital LLC
7.562 %
4,901,603 7.562 % 20 M $
Fidelity Management & Research Co. LLC
5.573 %
3,612,551 5.573 % 15 M $
Venrock Associates
5.253 %
3,405,133 5.253 % 14 M $
Casdin Capital LLC
4.947 %
3,206,380 4.947 % 13 M $
Brent Pfeiffenberger
2.269 %
1,470,704 2.269 % 6 M $
BlackRock Advisors LLC
2.245 %
1,454,892 2.245 % 6 M $

Company contact information

Century Therapeutics, Inc.

38th Street, 25 North 11th Floor

19104, Philadelphia

+

http://www.centurytx.com
address Century Therapeutics, Inc.(IPSC)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Century Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.96 USD
Average target price
14.83 USD
Spread / Average Target
+401.13%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CENTURY THERAPEUTICS, INC. Stock Century Therapeutics, Inc.
-9.64% 192M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.79% 43.84B
MODERNA, INC. Stock Moderna, Inc.
+5.83% 41.68B
LONZA GROUP AG Stock Lonza Group AG
+45.26% 41.25B
CELLTRION, INC. Stock Celltrion, Inc.
-11.96% 27.04B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+5.89% 25.53B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.96% 18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-2.99% 12.29B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+25.94% 12.29B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.72% 11.15B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. IPSC Stock
  4. Company Century Therapeutics, Inc.